BRPI0515403A - peptìdeo, corrente de ácido nucleico, formulação farmacêutica, formulação de vacina, anticorpo monoclonal e usos do peptìdeo e do anticorpo monoclonal - Google Patents

peptìdeo, corrente de ácido nucleico, formulação farmacêutica, formulação de vacina, anticorpo monoclonal e usos do peptìdeo e do anticorpo monoclonal

Info

Publication number
BRPI0515403A
BRPI0515403A BRPI0515403-0A BRPI0515403A BRPI0515403A BR PI0515403 A BRPI0515403 A BR PI0515403A BR PI0515403 A BRPI0515403 A BR PI0515403A BR PI0515403 A BRPI0515403 A BR PI0515403A
Authority
BR
Brazil
Prior art keywords
peptide
monoclonal antibody
nucleic acid
formulation
pharmaceutical formulation
Prior art date
Application number
BRPI0515403-0A
Other languages
English (en)
Inventor
Alicia Santos Savio
Ania Cabrales Rico
Osvaldo Reyes Acosta
Haydee Geronimo Perez
Celia Aurora Arrieta Agueero
Silvio Ernesto Perea Rodriguez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BRPI0515403A publication Critical patent/BRPI0515403A/pt
Publication of BRPI0515403B1 publication Critical patent/BRPI0515403B1/pt
Publication of BRPI0515403B8 publication Critical patent/BRPI0515403B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PEPTìDEO, CORRENTE DE áCIDO NUCLEICO, FORMULAçãO FARMACêUTICA, FORMULAçãO DE VACINA, ANTICORPO MONOCLONAL E USOS DO PEPTìDEO E DO ANTICORPO MONOCLONAL A presente invenção se relaciona com o ramo da farmacologia molecular e em particular com um peptídeo pertencente à seqüência da interleucina- 15 (IL- 15), que é capaz de inibir a atividade biológica desta molécula; análogos ou miméticos do dito peptídeo. Na presente invenção mostra-se que o peptídeo ao unir-se à subunidade alfa do receptor (IL- 15R) inibe a proliferação de células T induzida pela IL- 15 e a apoptose mediada por TNF. A invenção se relaciona além disso com o uso do peptídeo no tratamento de patologias onde a expressão anormal da IL-15 ou IL-15R está relacionada com o curso da doença.
BRPI0515403A 2004-09-17 2005-09-16 formulação farmacêutica capaz de inibir a atividade biológica da il-15, e, formulação de vacina BRPI0515403B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2004-0198 2004-09-17
CU20040198A CU23472A1 (es) 2004-09-17 2004-09-17 Péptido antagonista de la interleucina-15
PCT/CU2005/000007 WO2006029578A1 (es) 2004-09-17 2005-09-16 Péptido antagonista de la interleucina-15

Publications (3)

Publication Number Publication Date
BRPI0515403A true BRPI0515403A (pt) 2008-07-22
BRPI0515403B1 BRPI0515403B1 (pt) 2019-03-26
BRPI0515403B8 BRPI0515403B8 (pt) 2021-05-25

Family

ID=40262834

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515403A BRPI0515403B8 (pt) 2004-09-17 2005-09-16 formulação farmacêutica capaz de inibir a atividade biológica da il-15, e, formulação de vacina

Country Status (18)

Country Link
US (1) US7736638B2 (pt)
EP (1) EP1801119B1 (pt)
JP (1) JP4750795B2 (pt)
KR (1) KR101254113B1 (pt)
CN (1) CN101120015B (pt)
AR (1) AR051924A1 (pt)
AT (1) ATE434623T1 (pt)
AU (1) AU2005284529C1 (pt)
BR (1) BRPI0515403B8 (pt)
CA (1) CA2579798C (pt)
CU (1) CU23472A1 (pt)
DE (1) DE602005015131D1 (pt)
ES (1) ES2328717T3 (pt)
MX (1) MX2007002996A (pt)
PT (1) PT1801119E (pt)
RU (1) RU2396276C2 (pt)
WO (1) WO2006029578A1 (pt)
ZA (1) ZA200702128B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23716A1 (es) 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
CN101831435B (zh) * 2010-05-10 2013-09-11 昆山贝瑞康生物科技有限公司 小鼠il-15亚型蛋白的制备及其应用
EP2665486B1 (en) 2011-01-18 2019-12-25 Bioniz, LLC Compositions for modulating gamma-c-cytokine activity
PL404174A1 (pl) 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Zastosowanie pochodnych aminowych jako inhibitorów aktywności interleukiny 15
PL404138A1 (pl) 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
PL405506A1 (pl) 2013-09-30 2015-04-13 Warszawski Uniwersytet Medyczny Zastosowanie pochodnej kwasu 7-aminocefalosporanowego jako inhibitora aktywności biologicznej IL-15 i IL-2
PL405505A1 (pl) 2013-09-30 2015-04-13 Warszawski Uniwersytet Medyczny Zastosowanie pochodnej kwasu diaminodikarboksylowego jako inhibitora aktywności biologicznej IL-15 I IL-2
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
RU2689717C2 (ru) * 2014-01-08 2019-05-28 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Гетеродимерный белок il-15 и его применения
EP3237910B1 (en) 2014-12-23 2019-04-17 Siemens Healthcare Diagnostics Inc. Proteolytic digestion and determination of cardiac troponin
ES2950399T3 (es) * 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
US12600757B2 (en) 2017-04-07 2026-04-14 Bioniz Therapeutics, Inc. Peptides inhibiting gamma-c-cytokine activity and methods of use
CA3061328A1 (en) 2017-04-24 2018-11-01 University Of Massachusetts Diagnosis and treatment of vitiligo
KR101954214B1 (ko) * 2017-05-23 2019-03-06 (주)케어젠 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
CU24545B1 (es) 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
AU2019359475A1 (en) 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
MA71681A (fr) 2022-08-04 2025-05-30 Novartis Pharma Ag Inhibiteurs d'il-15 utiles pour le traitement de la dermatite atopique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2261433A1 (en) 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
AU686816B2 (en) * 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
WO1997041232A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
EP0849583A1 (en) * 1996-12-12 1998-06-24 European Community Split Hopkinson bar testing apparatus
ATE229342T1 (de) 1997-02-21 2002-12-15 Vlaams Interuniv Inst Biotech Verwendung von interleukin-15
GB9814892D0 (en) 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
WO2001002003A1 (en) 1999-07-06 2001-01-11 Bulfone Paus Silvia Method of treating psoriasis with il-15 antagonist
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.

Also Published As

Publication number Publication date
AU2005284529A1 (en) 2006-03-23
AR051924A1 (es) 2007-02-21
AU2005284529C1 (en) 2011-07-07
US20090136511A1 (en) 2009-05-28
MX2007002996A (es) 2007-05-16
JP2008512994A (ja) 2008-05-01
RU2396276C2 (ru) 2010-08-10
ES2328717T3 (es) 2009-11-17
RU2007114288A (ru) 2008-10-27
CN101120015A (zh) 2008-02-06
EP1801119A1 (en) 2007-06-27
ATE434623T1 (de) 2009-07-15
ZA200702128B (en) 2008-08-27
CU23472A1 (es) 2009-12-17
WO2006029578A1 (es) 2006-03-23
JP4750795B2 (ja) 2011-08-17
CA2579798A1 (en) 2006-03-23
KR101254113B1 (ko) 2013-04-15
PT1801119E (pt) 2009-09-21
BRPI0515403B8 (pt) 2021-05-25
CA2579798C (en) 2012-08-21
EP1801119B1 (en) 2009-06-24
DE602005015131D1 (de) 2009-08-06
KR20070072876A (ko) 2007-07-06
US7736638B2 (en) 2010-06-15
CN101120015B (zh) 2011-05-25
AU2005284529B2 (en) 2010-11-25
BRPI0515403B1 (pt) 2019-03-26

Similar Documents

Publication Publication Date Title
BRPI0515403A (pt) peptìdeo, corrente de ácido nucleico, formulação farmacêutica, formulação de vacina, anticorpo monoclonal e usos do peptìdeo e do anticorpo monoclonal
Chandra et al. Skeletal aging and osteoporosis: mechanisms and therapeutics
US11813304B2 (en) Compounds and methods for inhibiting phosphate transport
Chang et al. Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases
Kalia et al. Nucleotide, c-di-GMP, c-di-AMP, cGMP, cAMP,(p) ppGpp signaling in bacteria and implications in pathogenesis
NO20080084L (no) Molekyler som er i stand til a hemme bindingen mellom NGF og TrkA-reseptoren som analgetika med forlenget effekt
Wei et al. Dopamine transporter activity mediates amphetamine-induced inhibition of Akt through a Ca2+/calmodulin-dependent kinase II-dependent mechanism
Lee et al. Amino acid and cDNA sequence of bovine phosducin, a soluble phosphoprotein from photoreceptor cells.
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
CO6390070A2 (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas incluyendo receptor de factor de crecimiento tipo insulina -i
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
Miyashita et al. Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of nonsteroidal anti-inflammatory drugs
BR0314212C1 (pt) projeto de análogos a quimiocina de proteìna-10 (ip-10 ou cxcl10) induzìveis por interferon para o tratamento de doenças humanas
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
Serrano et al. Unifying the aminohexopyranose‐and peptidyl‐nucleoside antibiotics: Implications for antibiotic design
TAKEI‐TANIGUCHI et al. Interleukin‐17‐and protease‐activated receptor 2‐mediated production of CXCL1 and CXCL8 modulated by cyclosporine A, vitamin D3 and glucocorticoids in human keratinocytes
DK2044125T3 (da) Sammensætninger og fremgangsmåder til indgivelse af aktiverede anti-ras-antistoffer i celler
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
Hasannejad et al. Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs
Iqbal et al. Exploring antimicrobial potency, ADMET, and optimal drug target of a Non-ribosomal peptide Sevadicin from Bacillus pumilus, through in vitro assay and molecular dynamics simulation
CA2921037C (en) Use of trichostatin a in the treatment of multiple myeloma
Stefano et al. Dysregulated mitochondrial and chloroplast bioenergetics from a translational medical perspective
Meng et al. Rho is involved in periodontal tissue remodelling with experimental tooth movement in rats
Keszler et al. Activation of deoxycytidine kinase in lymphocytes is calcium dependent and involves a conformational change detectable by native immunostaining
Avram et al. QSAR Approaches Applied to Antidepressants Induced Neurogenesis-in vivo and in silico Applications

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.